ASRT vs. DERM, ANEB, LPTX, SLS, TPST, MNOV, IFRX, CUE, CRVS, and SPRO
Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Journey Medical (DERM), Anebulo Pharmaceuticals (ANEB), Leap Therapeutics (LPTX), SELLAS Life Sciences Group (SLS), Tempest Therapeutics (TPST), MediciNova (MNOV), InflaRx (IFRX), Cue Biopharma (CUE), Corvus Pharmaceuticals (CRVS), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical preparations" industry.
Assertio (NASDAQ:ASRT) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends, earnings and community ranking.
In the previous week, Journey Medical had 2 more articles in the media than Assertio. MarketBeat recorded 3 mentions for Journey Medical and 1 mentions for Assertio. Journey Medical's average media sentiment score of 0.59 beat Assertio's score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media.
Assertio presently has a consensus target price of $5.50, suggesting a potential upside of 587.50%. Journey Medical has a consensus target price of $8.50, suggesting a potential upside of 153.73%. Given Assertio's higher possible upside, research analysts plainly believe Assertio is more favorable than Journey Medical.
Journey Medical has a net margin of -4.87% compared to Assertio's net margin of -218.28%. Assertio's return on equity of 6.30% beat Journey Medical's return on equity.
Assertio has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.
49.0% of Assertio shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 7.9% of Assertio shares are held by company insiders. Comparatively, 19.4% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Journey Medical has lower revenue, but higher earnings than Assertio. Journey Medical is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.
Assertio received 102 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 58.86% of users gave Assertio an outperform vote.
Summary
Assertio and Journey Medical tied by winning 8 of the 16 factors compared between the two stocks.
Get Assertio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assertio Competitors List
Related Companies and Tools
